Riskpilot← Back to searchSign inGet full accessBio Vitos Pharma AB
ABActiveOrg 5568115272Nanna Svartz Väg 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 20100 employees
Revenue 2024
SEK 111K
-97% vs 2023
EBITDA margin
-2989.2%
-22% vs 2023
Equity ratio
97.6%
Financial strength
Net profit 2024
SEK -20,1M
+16% vs 2023
| Revenue | SEK 111K | -97% |
| EBITDA | SEK -3,3M | -22% |
| Net profit | SEK -20,1M | +16% |
| Total assets | SEK 16,3M | -29% |
| Equity | SEK 15,9M | -28% |
| Employees | 0 | — |
Legal name
Bio Vitos Pharma AB
Org number
5568115272
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 juni 2010
Share capital
SEK 5 733 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av verkställande direktören avseende löpande förvaltningsåtgärder trots att styrelsen inte är behörig. Styrelsen ska bestå av 3 styrelseledamöter och 0 styrelsesuppleanter. Registrerad behörig styrelse saknas. Därför saknas också uppgift om firmateckningsrätten. Registrerad kvalificerad revisor saknas. Då den verkställande direktören ska vara bosatt inom EES uppfyller bolaget numera inte bosättningskravet.
Company purpose
Bolaget har till föremål för sin verksamhet att, direkt eller indirekt, bedriva design, utveckling och försäljning av medicintekniska produkter, hälsopreparat, kosttillskott och läkemedel och därmed förenlig verksamhet.
Address
Nanna Svartz Väg 4
Phone
+46542022211
Email
info@biovitospharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 307 | 1 121 | 1 320 | 3 181 | 111 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −1 858 | −2 130 | −5 124 | −5 080 | −5 430 | −6 024 | −7 534 | −7 775 | −2 713 | −3 318 |
| Depreciation & amort. | −53 | −129 | −133 | −137 | −113 | −5 676 | −6 453 | −7 155 | −5 280 | −14 863 |
| EBIT | −1 911 | −2 259 | −5 257 | −5 217 | −5 543 | −11 700 | −13 987 | −14 930 | −7 993 | −18 181 |
| Net financials | −62 | −129 | −134 | −99 | −2 | 2 | 33 | 30 | −15 795 | −1 888 |
| Profit before tax | −1 973 | −2 388 | −5 391 | −5 317 | −5 545 | −11 698 | −13 954 | −14 900 | −23 788 | −20 069 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 973 | −2 388 | −5 391 | −5 317 | −5 545 | −11 698 | −13 954 | −14 900 | −23 788 | −20 069 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4 781 | 10 056 | 31 708 | 53 852 | 47 929 | 35 782 | 35 497 | 26 450 | 22 997 | 16 316 |
| Equity | 2 069 | 5 441 | 27 486 | 50 048 | 45 052 | 33 524 | 33 535 | 24 923 | 21 990 | 15 921 |
| Long-term debt | 2 180 | 2 036 | 1 707 | 835 | 206 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 532 | 2 579 | 2 515 | 2 969 | 2 671 | 2 258 | 1 962 | 1 527 | 1 007 | 395 |
| Total debt | 2 712 | 4 615 | 4 222 | 3 804 | 2 877 | 2 258 | 1 962 | 1 527 | 1 007 | 395 |
EBITDA margin
-2989.2%
This company
15.8%
Market median
-19019% vs market
20152024
Equity ratio
97.6%
This company
38.2%
Market median
+155% vs market
20152024
Return on equity
-126.1%
This company
18.4%
Market median
-785% vs market
20152024
Net profit margin
-18080.2%
This company
8.1%
Market median
-223312% vs market
20152024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20152024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JJ Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
FP Chief Auditor | Chief Auditor | 2022 | — | — |
JR Chief Auditor | Chief Auditor | 2026 | — | — |
JA Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
SR Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2024 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bio Vitos Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jon Jesper Birgemo | Chief Executive Officer | 0 companies |
| Filip Patrik Laurin | Chief Auditor | 0 companies |
| John Robert Nyholm | Chief Auditor | 0 companies |
| Joen Anders Emil Averstad | Chief Executive Officer | 0 companies |
| Sven Rohmann | Chief Executive Officer | 0 companies |
| Hans-Olof Joakim Friis | Board of Directors | 0 companies |
| John Erik Sebastian Brauns | Board of Directors | 0 companies |
| Per Hjalmar Olof Didrikson | Board of Directors | 0 companies |
| Vidar Sung Osen | Board of Directors | 0 companies |
| Jenni Fredrika Björnulfson | Board of Directors | 0 companies |
| Anders Mathias Karlsson | Board of Directors | 0 companies |
| Igor Lokot | Board of Directors | 0 companies |
| Lars Richard Sperrling Wall | Chairman | 0 companies |
| Robert Arinthian Simmons | Board of Directors | 0 companies |
| Helge Trettø Olsen | Chairman | 0 companies |
| Bo Lars Christer Ziedén | Board of Directors | 0 companies |
| Måns Anders Alfvén | Deputy Board Member | 0 companies |
| Anna Karin Klevby Dalgaard | Chairman | 0 companies |
| Torbjörn Mattias Koivisto | Board of Directors | 0 companies |
| Karin Cecilia Dahllöf | Board of Directors | 0 companies |